Conditions: Osteoporosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 44
Healthy volunteers: yes

Brief summary:
This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib

Detailed description:

Arms:
arm 1: Panel A - Healthy male subjects receiving Odanacatib arm 2: Panel A - Healthy male subjects receiving placebo arm 3: Panel B - Healthy female subjects receiving Odanacatib arm 4: Panel B - Healthy female subjects receiving placebo

Interventions: intervention 1: Odanacatib intervention 2: Comparator: Placebo
Intervention descriptions: intervention 1: Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks intervention 2: Oral Placebo tablet administered once weekly for 4 consecutive weeks

Protocol document: